At a glance
ClinicalIndex Comparison RecordEarly Ph 1Recruiting· 150 target
Drug / intervention
SPH5030 tabletsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
In Brief
A Early Phase 1 clinical trial evaluating SPH5030 tablets for HER2-positive Advanced Solid Tumors. Currently recruiting, targeting 150 participants across 17 sites.
Detailed Summary
To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2-positive Advanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Early Ph 1Recruiting
202220232024202520262027
Enrollment StartJan 2022
First PostedFeb 2022
TodayJul 2026
Primary CompletionDec 2026
First PostedFeb 17, 2022
Enrollment StartJan 21, 2022
Primary CompletionDec 21, 2026
TodayJul 1, 2026
Enrollment to primary: 4.9 yearsPosted 4.4 years agoPrimary completion in 6 months
Interventions
SPH5030 tabletsdrug
SPH5030 tablets orally once or twice daily.